CO2022005949A2 - Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo - Google Patents
Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitriloInfo
- Publication number
- CO2022005949A2 CO2022005949A2 CONC2022/0005949A CO2022005949A CO2022005949A2 CO 2022005949 A2 CO2022005949 A2 CO 2022005949A2 CO 2022005949 A CO2022005949 A CO 2022005949A CO 2022005949 A2 CO2022005949 A2 CO 2022005949A2
- Authority
- CO
- Colombia
- Prior art keywords
- enenitrile
- oxetan
- pent
- pyrazolo
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913029P | 2019-10-09 | 2019-10-09 | |
| US201962942877P | 2019-12-03 | 2019-12-03 | |
| PCT/US2020/054809 WO2021072095A1 (en) | 2019-10-09 | 2020-10-08 | Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022005949A2 true CO2022005949A2 (es) | 2022-07-29 |
Family
ID=73030241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0005949A CO2022005949A2 (es) | 2019-10-09 | 2022-05-06 | Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210106583A1 (https=) |
| EP (1) | EP4041240A1 (https=) |
| JP (2) | JP7784995B2 (https=) |
| KR (1) | KR20220079909A (https=) |
| CN (1) | CN115190798A (https=) |
| AU (1) | AU2020363873A1 (https=) |
| BR (1) | BR112022005575A2 (https=) |
| CA (1) | CA3153750A1 (https=) |
| CO (1) | CO2022005949A2 (https=) |
| IL (1) | IL291726A (https=) |
| MX (1) | MX2022004283A (https=) |
| WO (1) | WO2021072095A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025090703A1 (en) * | 2023-10-25 | 2025-05-01 | Principia Biopharma Inc. | Treatment of chronic spontaneous urticaria by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[4-(oxetan-3- yl)piperazin-l-yl]pent-2-enenitrile |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| PT3236953T (pt) | 2014-12-24 | 2021-01-29 | Principia Biopharma Inc | Dosagem específica de sítio de um inibidor de btk |
| CN115054586B (zh) * | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
-
2020
- 2020-10-08 KR KR1020227015113A patent/KR20220079909A/ko active Pending
- 2020-10-08 JP JP2022520968A patent/JP7784995B2/ja active Active
- 2020-10-08 CA CA3153750A patent/CA3153750A1/en active Pending
- 2020-10-08 BR BR112022005575A patent/BR112022005575A2/pt unknown
- 2020-10-08 US US17/066,300 patent/US20210106583A1/en not_active Abandoned
- 2020-10-08 CN CN202080083113.6A patent/CN115190798A/zh active Pending
- 2020-10-08 EP EP20797943.6A patent/EP4041240A1/en active Pending
- 2020-10-08 AU AU2020363873A patent/AU2020363873A1/en active Pending
- 2020-10-08 WO PCT/US2020/054809 patent/WO2021072095A1/en not_active Ceased
- 2020-10-08 MX MX2022004283A patent/MX2022004283A/es unknown
-
2022
- 2022-03-27 IL IL291726A patent/IL291726A/en unknown
- 2022-05-06 CO CONC2022/0005949A patent/CO2022005949A2/es unknown
- 2022-09-30 US US17/957,073 patent/US20230158033A1/en active Pending
-
2025
- 2025-07-18 JP JP2025120944A patent/JP2025157438A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4041240A1 (en) | 2022-08-17 |
| KR20220079909A (ko) | 2022-06-14 |
| US20230158033A1 (en) | 2023-05-25 |
| MX2022004283A (es) | 2022-07-12 |
| CA3153750A1 (en) | 2021-04-15 |
| CN115190798A (zh) | 2022-10-14 |
| JP2025157438A (ja) | 2025-10-15 |
| IL291726A (en) | 2022-05-01 |
| BR112022005575A2 (pt) | 2022-06-21 |
| JP2022552199A (ja) | 2022-12-15 |
| JP7784995B2 (ja) | 2025-12-12 |
| TW202128172A (zh) | 2021-08-01 |
| US20210106583A1 (en) | 2021-04-15 |
| AU2020363873A1 (en) | 2022-04-14 |
| WO2021072095A1 (en) | 2021-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Murphy et al. | Advances in supportive care for late effects of head and neck cancer | |
| CY1123110T1 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CY1114215T1 (el) | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| CY1116215T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| ECSP045140A (es) | Formulaciones farmacéuticas derivadas del platino | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| Uchida et al. | The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| JOP20200015A1 (ar) | توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين | |
| Gregoire et al. | Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| MX390667B (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| MX2021011746A (es) | Formulacion de combinacion triple de dosis baja. | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| JOP20230219A1 (ar) | نظام جرعات سوتوراسيب | |
| CO2022005949A2 (es) | Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo | |
| EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño |